U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 27 results

Status:
US Previously Marketed
First approved in 2012

Class (Stereo):
CHEMICAL (ABSOLUTE)



Omacetaxine mepesuccinate (trade name Synribo) formerly named as homoharringtonine or HHT, is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). It is a natural ester of the alkaloid cephalotaxine from ...
Status:
US Approved Rx (2012)
First approved in 2012

Class (Stereo):
CHEMICAL (ACHIRAL)



Ponatinib (trade name Iclusig, previously AP24534) is developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph ) acute lymphoblastic leukemia (ALL). Ponatinib has been designed to...
Status:
US Approved Rx (2023)
First approved in 2012

Class (Stereo):
CHEMICAL (ACHIRAL)



Bosutinib (trade name Bosulif) originally synthesized by Wyeth, it is being developed by Pfizer. Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patien...
Status:
US Approved Rx (2021)
First approved in 2011

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ruxolitinib (trade names Jakafi and Jakavi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow. It is also being investiga...
Status:
US Approved Rx (2022)
First approved in 2008

Class (Stereo):
CHEMICAL (ACHIRAL)

Targets:


Bendamustine, brand name Treanda, is a chemotherapeutic agent that displays a unique pattern of cytotoxicity compared with conventional alkylating agents. Treanda is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL), in ...
Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)



Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...
Status:
US Approved Rx (2017)
First approved in 2006

Class (Stereo):
CHEMICAL (ABSOLUTE)



Decitabine was first synthesized by Pliml and Sorm in the Institute of Organic Chemistry, Czechoslovak Academy of Sciences in 1964. Later, the drug was approved by FDA for the treatment of myelodysplastic syndromes in patients with cancer. Upon admin...
Status:
US Approved Rx (2024)
First approved in 2005

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:


Arranon is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. It is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleoti...
Status:
US Approved Rx (2019)
First approved in 2001

Class (Stereo):
CHEMICAL (ACHIRAL)



Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It...
Status:
US Approved Rx (2000)
First approved in 1993

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cladribine is used for the treatment of hairy cell leukemia and multiple sclerosis (MS). As a purine analog, it is a synthetic anti-cancer agent that also suppresses the immune system. Chemically, it mimics the nucleoside adenosine and thus inhibits ...